608 related articles for article (PubMed ID: 16112026)
21. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
22. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
23. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
24. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
Díaz-Ortega JL; Bennett JV; Castañeda D; Martinez D; de Castro JF
Vaccine; 2010 Oct; 28(44):7228-32. PubMed ID: 20800111
[TBL] [Abstract][Full Text] [Related]
25. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
26. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
27. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
28. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
[TBL] [Abstract][Full Text] [Related]
29. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
30. Long-term persistence of antibodies after one or two doses of MMR-vaccine.
Vandermeulen C; Mathieu R; Geert LR; Pierre VD; Karel H
Vaccine; 2007 Sep; 25(37-38):6672-6. PubMed ID: 17692439
[TBL] [Abstract][Full Text] [Related]
31. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
32. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
33. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
34. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Shane Pankratz V; Jacobsen SJ; Poland GA
Vaccine; 2004 May; 22(15-16):1914-20. PubMed ID: 15121303
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
36. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.
Aytac S; Yalcin SS; Cetin M; Yetgin S; Gumruk F; Tuncer M; Yurdakok K; Gurgey A
Pediatr Hematol Oncol; 2010 Aug; 27(5):333-43. PubMed ID: 20469978
[TBL] [Abstract][Full Text] [Related]
37. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
38. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
Pareek M; Pattison HM
Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
